Accessibility Menu
 
Abeona Therapeutics logo

Abeona Therapeutics

(NASDAQ) ABEO

Current Price$4.46
Market Cap$246.03M
Since IPO (1996)-100%
5 Year-92%
1 Year-13%
1 Month-13%

Abeona Therapeutics Financials at a Glance

Market Cap

$246.03M

Revenue (TTM)

$5.82M

Net Income (TTM)

$71.18M

EPS (TTM)

$1.00

P/E Ratio

4.55

Dividend

$0.00

Beta (Volatility)

0.89 (Low)

Price

$4.46

Volume

41,800

Open

$4.55

Previous Close

$4.46

Daily Range

$4.43 - $4.57

52-Week Range

$3.93 - $7.54

ABEO: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Abeona Therapeutics

Industry

Biotechnology

Employees

226

CEO

Vishwas Seshadri, PhD, MBA

Headquarters

Cleveland, NY 10019, US

ABEO Financials

Key Financial Metrics (TTM)

Gross Margin

26%

Operating Margin

-15%

Net Income Margin

12%

Return on Equity

70%

Return on Capital

-47%

Return on Assets

32%

Earnings Yield

21.98%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$246.03M

Shares Outstanding

54.19M

Volume

41.80K

Short Interest

0.00%

Avg. Volume

1.21M

Financials (TTM)

Gross Profit

$4.29M

Operating Income

$89.45M

EBITDA

$85.89M

Operating Cash Flow

$76.33M

Capital Expenditure

$7.97M

Free Cash Flow

$84.30M

Cash & ST Invst.

$191.40M

Total Debt

$24.97M

Abeona Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$5.42M

N/A

Gross Profit

$1.72M

+321.6%

Gross Margin

31.73%

N/A

Market Cap

$246.03M

N/A

Market Cap/Employee

$1.81M

N/A

Employees

136

N/A

Net Income

$20.46M

-120.2%

EBITDA

$183.17M

-2363.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$166.44M

+122.9%

Accounts Receivable

$6.71M

+306.5%

Inventory

$5.49M

N/A

Long Term Debt

$11.88M

-27.1%

Short Term Debt

$13.09M

+93.9%

Return on Assets

32.42%

N/A

Return on Invested Capital

-47.08%

N/A

Free Cash Flow

$19.11M

-11.3%

Operating Cash Flow

$17.95M

-8.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VYGRVoyager Therapeutics, Inc.
$3.85+2.81%
FHTXFoghorn Therapeutics Inc.
$5.00+2.25%
ARCTArcturus Therapeutics Holdings Inc.
$6.63-1.34%
PBYIPuma Biotechnology, Inc.
$6.12-0.49%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%
QQQInvesco QQQ Trust
$582.06-0.02%
VRTVertiv
$255.88-0.05%

Questions About ABEO

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.